“beigene” Archives

in
Entry Author Date Location
Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China 09/30/20 New York
Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More 07/17/20 National
Amgen Doubles Down on BeiGene Collaboration, Investing $421M More 07/13/20 San Francisco
AstraZeneca Chooses China for R&D and AI Centers, $1B Biotech Fund 11/06/19 National
Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More 11/01/19 National
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
SpringWorks, Armed with Ex-Pfizer Cancer Drugs, Reloads with $125M 04/01/19 New York
BeiGene Puts Up $10M to Use Ambrx’s Drug Development Technology 03/07/19 San Diego
MEI Pharma Inks Cancer Drug Deal with Japan’s Kyowa Hakko Kirin 11/05/18 San Diego
Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away 09/07/18 National
Brii Biosciences Debuts with a China Pharma Strategy Backed by $260M 05/24/18 Raleigh Durham
Bio Roundup: Spark’s Road Ahead, Juno Rumors, Merck’s Big Day & More 01/19/18 National
Bio Roundup: BCRA Fireworks, Shkreli Muzzled, Endo Pulls Drug & More 07/07/17 National
Celgene Builds Up Cancer Drug Pipeline With BeiGene Deal 07/06/17 New York
Many Biotechs Need Inside IPO Help, But Selecta Is An Extreme Case 06/22/16 Boston
Syndax Cuts Price But Bags $53M in Second IPO Try 03/02/16 Boston
Proteostasis Cuts Price But Heads to Nasdaq After $50M IPO 02/11/16 Boston
Page 1 of 1